Esta página aún no está traducida al español y se muestra en inglés. Estamos trabajando en su traducción.

Esta referencia está disponible actualmente en inglés. La versión en español está en preparación.

Low Dose Naltrexone: What the Published Trials Report

Por Benn Bluestein-Veyra, M.Sc. en Química Orgánica · Actualizado el 9 de noviembre de 2026

ExaVeyra Sciences es un proveedor B2B con sede en Miami que suministra exosomas para uso estético tópico a clínicas con licencia, y trabaja con una farmacia de preparados compuestos 503A que prepara formulaciones para prescriptores con licencia según prescripciones individuales.

Qué cubre esta página, quién puede comprar a ExaVeyra, y qué se suministra
PreguntaRespuesta
Qué cubre esta páginaLow dose naltrexone evidence: what the crossover trials, the Danish FINAL trial, the Crohn and MS population studies and the meta-analyses report.
Quién puede hacer pedidosClínicas y profesionales con licencia profesional activa y NPI verificados por ExaVeyra. Los pedidos de exosomas requieren además un reconocimiento firmado de uso profesional.
Qué se envía y cómoLas formulaciones compuestas las prepara y dispensa nuestra farmacia asociada 503A según una prescripción individual del profesional con licencia, y se envían desde la farmacia. Las sustancias controladas las dispensa la farmacia con su propio registro de la DEA.

The published low dose naltrexone trials are small, and the largest one was negative on its primary outcome. Younger and colleagues reported a greater reduction in daily pain than placebo in a 31-woman crossover trial in a fibromyalgia population in 2013, Smith and colleagues reported a higher disease activity index response rate than placebo in 40 adults with active Crohn's disease in 2011, and the 99-woman Danish FINAL trial published in 2024 "did not show that treatment with low-dose naltrexone was superior to placebo in relieving pain" in women with fibromyalgia.[1][2][3] Four systematic reviews and meta-analyses published between 2023 and 2025 pool small and overlapping sets of trials and reach different conclusions, from a low strength of evidence and no superiority over placebo to a pooled reduction in fibromyalgia pain.[4][5][6][7]

This page reports what the approved naltrexone labels state about the molecule, what the mechanistic literature proposes for low doses, what each trial and review reports with its design and participant count, and where naltrexone stands under section 503A of the Federal Food, Drug, and Cosmetic Act.[8][9]

The approved labels describe naltrexone as a pure opioid antagonist with a long-acting active metabolite

The label for Naltrexone Hydrochloride Tablets USP states that the drug "is a pure opioid antagonist" that "markedly attenuates or completely blocks, reversibly, the subjective effects of opioids", with "few, if any, intrinsic actions besides its opioid blocking properties".[8] The Vivitrol label adds that naltrexone has its "highest affinity for the mu opioid receptor" and that "occupation of opioid receptors by naltrexone may block the effects of endogenous opioid peptides".[10] On pharmacokinetics, the tablet label records oral bioavailability estimates "ranging from 5% to 40%" because of first pass metabolism, activity attributed to "both parent and the 6-β-naltrexol metabolite", and mean elimination half-lives of 4 hours for naltrexone and 13 hours for the metabolite.[8]

The tablets are approved "in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids", and FDA lists extended-release naltrexone among its approved medications for opioid use disorder.[8][11] The first product, ReVia (NDA 018932), was approved on 20 November 1984 as a new molecular entity; Drugs@FDA lists it as discontinued with a Federal Register determination that it "was not discontinued or withdrawn for safety or effectiveness reasons", and DailyMed carries naltrexone hydrochloride tablets under the USP name, including the SpecGx label cited here.[8][12] Both labels contraindicate the drug in patients receiving opioid analgesics, patients currently dependent on opioids, patients in acute opioid withdrawal, and anyone who has failed a naloxone challenge or has a positive urine opioid screen.[8][10]

The low dose hypothesis rests on glial TLR4 antagonism and transient opioid receptor blockade

Younger, Parkitny and McLain reviewed the mechanistic case in 2014, proposing that low doses "may operate as a novel anti-inflammatory agent in the central nervous system, via action on microglial cells", with effects that "appear to be entirely independent from naltrexone's better-known activity on opioid receptors". They wrote that "the use of LDN for chronic disorders is still highly experimental" because "published trials have low sample sizes, and few replications have been performed".[13]

The toll-like receptor 4 evidence comes from cell models. Wang and colleagues characterized the opioid-inactive (+)-isomers of naltrexone and naloxone in mouse microglial cells, primary rat microglia and rat peritoneal macrophages and reported that both were equipotent inhibitors of LPS-induced TLR4 downstream signaling, acting as "TRIF-IFN regulatory factor 3 axis-biased TLR4 antagonists" without inhibiting the NF-κB, p38 or JNK arms.[14] Toljan and Vrooman summarized the two proposed actions as reduced glial inflammatory signaling through TLR4 and systemic upregulation of endogenous opioid signaling by transient receptor blockade, and noted that these features "have been only recently and still scarcely scientifically evaluated".[15] Patten, Schultz and Berlau concluded in 2018 that the evidence supported tolerability in the multiple sclerosis, fibromyalgia and Crohn's disease populations studied, with "fewer studies" supporting efficacy and most of those "focusing on subjective measures such as quality of life or self-reported pain".[16]

What the crossover trials report in women with fibromyalgia

Younger and Mackey's 2009 pilot enrolled ten women meeting fibromyalgia criteria in a single-blind crossover design. They reported a greater than 30 percent reduction in symptoms over placebo, improved mechanical and heat pain thresholds, rare and transient side effects including insomnia and vivid dreams, and that baseline erythrocyte sedimentation rate predicted over 80 percent of the variance in response.[17] The 2013 replication was a randomized, double-blind, placebo-controlled, counterbalanced crossover trial in 31 women measuring daily self-reported pain. The authors reported a 28.8 percent reduction from baseline pain on the drug against 18.0 percent on placebo, improved mood and life satisfaction, no improvement in fatigue or sleep, and tolerability equal to placebo with no serious side effects, and they wrote that "parallel-group randomized controlled trials are needed to fully determine the efficacy of the medication".[1] A 2017 single-blind crossover study in eight women reported reductions across a plasma cytokine panel that included IL-1β, IL-6 and TNF-α alongside a 15 percent reduction in pain.[18]

What the Danish FINAL trial reports: no superiority over placebo on the primary outcome

The parallel-group trial the 2013 authors called for was the FINAL study at Odense University Hospital, registered as NCT04270877, randomized and quadruple-masked, with 99 participants enrolled and a study period from 6 January 2021 to 27 December 2022.[19] Bruun and colleagues screened 158 women with fibromyalgia and randomized 99 to a daily oral low dose of naltrexone or an identical-appearing placebo for 12 weeks, with change in pain intensity on an 11-point numeric rating scale as the primary outcome; the registry record describes once-daily oral tablets in both arms.[19] Mean pain intensity fell by 1.3 points on naltrexone and 0.9 points on placebo, a between-group difference of 0.34 points with a confidence interval that crossed zero. Adverse events occurred in 84 percent of the naltrexone group and 86 percent of the placebo group, one serious adverse event occurred in the placebo group, and no participant was lost to follow-up. The authors concluded that the study "did not show that treatment with low-dose naltrexone was superior to placebo in relieving pain" and suggested that a signal on memory problems be examined in future trials.[3]

What the Crohn's disease and multiple sclerosis population trials report

Smith and colleagues at Penn State randomized 40 adults with active Crohn's disease to a daily oral low dose of naltrexone or placebo for 12 weeks. They reported that 88 percent of the naltrexone group had at least a 70-point decline in the Crohn's Disease Activity Index against 40 percent on placebo, an endoscopic response in 78 percent against 28 percent, and fatigue as the only side effect that differed, more frequent on placebo.[2] Their 2013 pediatric pilot randomized 14 children aged 8 to 17 to weight-based naltrexone or placebo for eight weeks followed by open-label treatment and reported no serious adverse events, a fall in the Pediatric Crohn's Disease Activity Index and 25 percent meeting a remission score.[20]

Two placebo-controlled crossover trials in multiple sclerosis populations appeared in 2010. Cree, Kornyeyeva and Goodin enrolled 80 adults with clinically definite multiple sclerosis for eight weeks of nightly low dose naltrexone; 60 completed. They reported improvement on mental health quality of life measures and no serious adverse events, and stated that "the high rate of subject dropout and data management errors substantially reduced the trial's statistical power".[21] Sharafaddinzadeh and colleagues enrolled 96 patients aged 15 to 65 with relapsing-remitting or secondary progressive disease at two Iranian universities for 17 weeks, reported no meaningful between-group difference on the MSQoL-54 quality of life domains, and concluded that the drug's "efficacy is under question" and that "probably a long duration trial is needed in the future".[22]

TrialPopulation enrolledDesignParticipantsPrimary finding as the authors report it
Younger and Mackey 2009Women meeting fibromyalgia criteriaSingle-blind crossover pilot10Symptom reduction over placebo; ESR predicted response
Younger 2013Women with fibromyalgiaRandomized double-blind crossover31Greater reduction in daily pain than placebo; no change in fatigue or sleep
Smith 2011Adults with active Crohn's diseaseRandomized double-blind parallel40Higher CDAI response and endoscopic response than placebo
Smith 2013Children with moderate to severe Crohn's diseaseRandomized pilot then open label14No serious adverse events; PCDAI fell
Cree 2010Adults with clinically definite MSDouble-masked placebo-controlled crossover80 (60 completed)Mental health quality of life improved; power reduced by dropout
Sharafaddinzadeh 2010Patients aged 15 to 65 with RRMS or SPMSRandomized double-blind crossover96No meaningful between-group difference on MSQoL-54
Bruun 2024 (FINAL)Women with fibromyalgiaRandomized quadruple-masked parallel99No superiority over placebo on pain intensity

The systematic reviews and meta-analyses disagree, and each calls the evidence limited

Partridge and colleagues found three efficacy trials and two mechanism studies in the fibromyalgia population to May 2022, reported "some evidence to suggest LDN reduces pain and increases quality of life", noted that all studies "were based on small sample sizes, were restricted to women and the risk of bias was assessed to be high" with "some evidence of publication bias", and graded the randomized evidence as low strength.[4] Vatvani and colleagues pooled four randomized trials with 222 participants to May 2024 and reported a mean pain score reduction of 0.86 points against placebo, no difference on the Fibromyalgia Impact Questionnaire Revised, higher rates of vivid dreams and nausea, and no difference in serious adverse events.[5]

Ologunowa and colleagues pooled eight clinical trials to the same date and reported that pain and symptom severity fell from baseline in the naltrexone arms while the between-group differences against placebo were not significant, with high heterogeneity, concluding that the effects "were not superior to placebo".[6] Hegde and colleagues pooled seven randomized trials across chronic pain populations in 2025 and reported no overall difference against control, a fibromyalgia subgroup standardized mean difference of 0.34 in favor of naltrexone, and an adverse event incidence rate ratio of 1.4 against placebo.[7] The four syntheses admit different sets of trials, from three to eight, and Partridge and colleagues graded the randomized evidence as low strength.[4][5][6][7]

The safety findings the labels and the trials report

The tablet label states under Hepatotoxicity that "cases of hepatitis and clinically significant liver dysfunction were observed in association with naltrexone hydrochloride exposure during the clinical development program and in the postmarketing period", with other causes often present.[8] The Vivitrol label adds warnings on precipitated opioid withdrawal "that may be severe enough to require hospitalization", vulnerability to opioid overdose after the blockade wanes, depression and suicidality, and injection site reactions specific to the intramuscular product.[10] The low dose trials report vivid dreams, insomnia and nausea as the recurring adverse events and no serious adverse events attributed to the drug, and the FINAL trial's adverse event rate matched placebo; the Hegde analysis is the one synthesis to report a higher adverse event incidence than placebo.[3][5][7][17] The label contraindication for concurrent opioid analgesics applies to the molecule at any strength, and the 2009 Stanford pilot enrolled only women not taking an opioid medication.[8][17]

Naltrexone hydrochloride has a USP monograph and approved products, so section 503A permits compounding it from a qualifying bulk substance

Section 503A(b)(1)(A)(i) permits a licensed pharmacist or physician to compound with bulk drug substances that "comply with the standards of an applicable United States Pharmacopoeia or National Formulary monograph, if a monograph exists", or, "if such a monograph does not exist, are drug substances that are components of drugs approved by the Secretary", or, failing both, that appear on the list FDA develops by regulation; the substance must also come from an FDA-registered establishment and be "accompanied by valid certificates of analysis".[9] FDA states the same three routes on its 503A bulk substances page.[23] Naltrexone hydrochloride is listed as a USP ingredient on the approved tablet label and is the active ingredient of approved products from NDA 018932 onward, so it qualifies under the monograph route and does not depend on the 503A bulks list.[8][12] That list, codified at 21 CFR 216.23, names six substances as of 5 November 2026 and four that FDA declined to list, and naltrexone appears in neither group.[24] FDA's compounding laws page states that compounded drugs "are not FDA-approved" and are not reviewed for safety, effectiveness or quality before they reach patients.[25]

The remaining condition is section 503A(b)(1)(D), which bars compounding "regularly or in inordinate amounts" drug products that are "essentially copies of a commercially available drug product", except where a change "made for an identified individual patient" produces "a significant difference, as determined by the prescribing practitioner".[9] FDA's 2018 guidance treats a compounded product in "an easily substitutable strength" of the same active ingredient by the same route as essentially a copy unless the prescriber documents that determination, and states that other factors "such as a lower price, are not sufficient to establish that the compounded drug product is not essentially a copy".[26] Whether a low strength capsule or liquid differs enough from the approved tablet is the prescriber's documented determination under that guidance.[26]

What the sources leave for the practitioner to decide

The record a practice can rely on is the set of statements above: approved labels that describe the molecule and its warnings, a mechanistic hypothesis built on cell models and small cytokine studies, small positive trials of between eight and 80 participants, most of them crossover designs, one adequately powered parallel trial in fibromyalgia that did not meet its primary endpoint, and four syntheses that disagree.[3][7][8][13]

  • The population a cited trial enrolled, since no trial listed here enrolled a general chronic pain population and the FINAL result applies to women with fibromyalgia.
  • The design behind a cited effect size, since most of the positive trials are crossover studies and the one parallel trial in fibromyalgia reported no superiority.
  • The label contraindications, which apply to the molecule rather than to a strength.
  • The prescriber's documented significant difference where a compounded strength replaces the approved tablet, in the form FDA's guidance describes.
  • The certificate of analysis for the bulk naltrexone hydrochloride, which section 503A requires for each bulk drug substance.

Compounded low dose naltrexone reaches a practice through ExaVeyra's licensed 503A pharmacy partner on a patient-specific prescription, with a certificate of analysis for each lot available on request, as section 503A requires for each bulk drug substance.[9] The decision to prescribe, the population, the strength and the monitoring plan belong to the prescribing practitioner.

This article summarizes published research and federal regulation for licensed practitioner education. It is not legal advice, medical advice, or regulatory guidance, and it does not establish that any particular product or practice is compliant. Confirm current federal and state obligations with qualified counsel.

Referencias comentadas

Numeradas en el orden en que se citan en el texto. Cada fuente lleva una nota sobre lo que respalda en esta página; los artículos revisados por pares se listan con revista, volumen, número y páginas, y las fuentes primarias son regulaciones, documentos de agencias, guías y declaraciones de posición.

  1. 1.Peer-reviewedYounger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis and Rheumatism. 2013;65(2):529-538. https://pubmed.ncbi.nlm.nih.gov/23359310/Annotation: The 31-woman crossover trial: greater reduction in daily pain than placebo, no change in fatigue or sleep, tolerability equal to placebo, and the call for parallel-group trials.
  2. 2.Peer-reviewedSmith JP, Bingaman SI, Ruggiero F, Mauger DT, Mukherjee A, McGovern CO, Zagon IS. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial. Digestive Diseases and Sciences. 2011;56(7):2088-2097. https://pubmed.ncbi.nlm.nih.gov/21380937/Annotation: The 40-adult double-blind trial in active Crohn's disease: CDAI response and endoscopic response rates against placebo, and fatigue as the only side effect that differed, more frequent on placebo.
  3. 3.Peer-reviewedDue Bruun K, Christensen R, Amris K, Vaegter HB, Blichfeldt-Eckhardt MR, Bye-Møller L, Holsgaard-Larsen A, Toft P. Naltrexone 6 mg once daily versus placebo in women with fibromyalgia: a randomised, double-blind, placebo-controlled trial. The Lancet Rheumatology. 2024;6(1):e31-e39. https://pubmed.ncbi.nlm.nih.gov/38258677/Annotation: The FINAL trial: 99 women randomized, quadruple masked, primary outcome of pain intensity not met, adverse event rates matching placebo, and the authors' conclusion of no superiority.
  4. 4.Peer-reviewedPartridge S, Quadt L, Bolton M, Eccles J, Thompson C, Colasanti A, Bremner S, Jones CI, Bruun KD, Van Marwijk H. A systematic literature review on the clinical efficacy of low dose naltrexone and its effect on putative pathophysiological mechanisms among patients diagnosed with fibromyalgia. Heliyon. 2023;9(5):e15638. https://pubmed.ncbi.nlm.nih.gov/37206027/Annotation: Three efficacy trials and two mechanism studies to May 2022: small samples restricted to women, high risk of bias, some evidence of publication bias, low strength of randomized evidence.
  5. 5.Peer-reviewedVatvani AD, Patel P, Hariyanto TI, Yanto TA. Efficacy and safety of low-dose naltrexone for the management of fibromyalgia: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. The Korean Journal of Pain. 2024;37(4):367-378. https://pubmed.ncbi.nlm.nih.gov/39344363/Annotation: Four randomized trials with 222 participants to May 2024: lower pain scores and higher pressure pain threshold than placebo, no difference on the FIQR, and higher rates of vivid dreams and nausea.
  6. 6.Peer-reviewedOlogunowa A, Otoo MN, Caffrey AR, Buchanan A, Eze UJ, Vyas A. Efficacy of Low-Dose Naltrexone in Treating Patients with Fibromyalgia: systematic Review and Meta-Analysis. Journal of Pain and Palliative Care Pharmacotherapy. 2025;39(3):363-373. https://pubmed.ncbi.nlm.nih.gov/40272382/Annotation: Eight clinical trials to May 2024: pain and symptom severity fell from baseline, but between-group differences against placebo were not significant, with high heterogeneity.
  7. 7.Peer-reviewedHegde NC, Mishra A, V D, Maiti R, Hota D, Srinivasan A. Low Dose Naltrexone In The Management Of Chronic Pain Syndrome: A Meta-Analysis Of Randomized Controlled Clinical Trials. Current Pain and Headache Reports. 2025;29(1):96. https://pubmed.ncbi.nlm.nih.gov/40540205/Annotation: Seven randomized trials across chronic pain populations: no overall difference against control, a fibromyalgia subgroup effect in favor of naltrexone, and a higher adverse event incidence than placebo.
  8. 8.Official sourceDailyMed (NIH National Library of Medicine), Naltrexone Hydrochloride Tablets USP prescribing information (SpecGx LLC, revised 05/2026). Accessed 8 November 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06ff2d5a-e62b-4fa4-bbdb-01938535bc65
  9. 9.Regulatory21 U.S.C. 353a, Pharmacy compounding (United States Code, 2024 edition, GPO). Accessed 8 November 2026. https://www.govinfo.gov/content/pkg/USCODE-2024-title21/html/USCODE-2024-title21-chap9-subchapV-partA-sec353a.htm
  10. 10.Official sourceDailyMed (NIH National Library of Medicine), Vivitrol (naltrexone for extended-release injectable suspension) prescribing information (Alkermes, revised December 2025). Accessed 8 November 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cd11c435-b0f0-4bb9-ae78-60f101f3703f
  11. 11.RegulatoryFDA, Medications for Opioid Use Disorder (MOUD) (content current as of 4 November 2026). Accessed 8 November 2026. https://www.fda.gov/drugs/information-drug-class/information-about-medications-opioid-use-disorder-moud
  12. 12.RegulatoryFDA, Drugs@FDA, NDA 018932 ReVia (naltrexone hydrochloride) tablets: approval history and Federal Register determination note. Accessed 8 November 2026. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018932
  13. 13.Peer-reviewedYounger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clinical Rheumatology. 2014;33(4):451-459. https://pubmed.ncbi.nlm.nih.gov/24526250/Annotation: The microglial anti-inflammatory hypothesis for low doses, its claimed independence from opioid receptor activity, and the authors' statement that the use remains highly experimental with small, unreplicated trials.
  14. 14.Peer-reviewedWang X, Zhang Y, Peng Y, Hutchinson MR, Rice KC, Yin H, Watkins LR. Pharmacological characterization of the opioid inactive isomers (+)-naltrexone and (+)-naloxone as antagonists of toll-like receptor 4. British Journal of Pharmacology. 2016;173(5):856-869. https://pubmed.ncbi.nlm.nih.gov/26603732/Annotation: Cell-model evidence that the opioid-inactive isomers inhibit LPS-induced TLR4 signaling as TRIF-IRF3 axis-biased antagonists in microglia and macrophages.
  15. 15.Peer-reviewedToljan K, Vrooman B. Low-Dose Naltrexone (LDN): Review of Therapeutic Utilization. Medical Sciences. 2018;6(4):82. https://pubmed.ncbi.nlm.nih.gov/30248938/Annotation: The two proposed low dose actions, glial TLR4 modulation and transient opioid receptor blockade, and the statement that these features have been only recently and scarcely evaluated.
  16. 16.Peer-reviewedPatten DK, Schultz BG, Berlau DJ. The Safety and Efficacy of Low-Dose Naltrexone in the Management of Chronic Pain and Inflammation in Multiple Sclerosis, Fibromyalgia, Crohn's Disease, and Other Chronic Pain Disorders. Pharmacotherapy. 2018;38(3):382-389. https://pubmed.ncbi.nlm.nih.gov/29377216/Annotation: The T and B cell and TLR4 hypothesis as stated, and the conclusion that evidence supports tolerability while fewer studies, mostly on subjective measures, support efficacy.
  17. 17.Peer-reviewedYounger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Medicine. 2009;10(4):663-672. https://pubmed.ncbi.nlm.nih.gov/19453963/Annotation: The first low dose naltrexone pilot: ten women, single-blind crossover, symptom reduction over placebo, improved pain thresholds, transient side effects, and ESR as a predictor of response.
  18. 18.Peer-reviewedParkitny L, Younger J. Reduced Pro-Inflammatory Cytokines after Eight Weeks of Low-Dose Naltrexone for Fibromyalgia. Biomedicines. 2017;5(2):16. https://pubmed.ncbi.nlm.nih.gov/28536359/Annotation: The eight-woman single-blind crossover cytokine study: reductions across a plasma cytokine panel alongside a modest reduction in pain.
  19. 19.Official sourceClinicalTrials.gov, NCT04270877, Fibromyalgia and Naltrexone: The FINAL Study (Odense University Hospital; 99 enrolled; completed). Accessed 8 November 2026. https://clinicaltrials.gov/study/NCT04270877
  20. 20.Peer-reviewedSmith JP, Field D, Bingaman SI, Evans R, Mauger DT. Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn's disease: a pilot study. Journal of Clinical Gastroenterology. 2013;47(4):339-345. https://pubmed.ncbi.nlm.nih.gov/23188075/Annotation: The 14-child pilot: randomized then open-label, no serious adverse events, a fall in the Pediatric Crohn's Disease Activity Index, and the remission proportion the authors reported.
  21. 21.Peer-reviewedCree BA, Kornyeyeva E, Goodin DS. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Annals of Neurology. 2010;68(2):145-150. https://pubmed.ncbi.nlm.nih.gov/20695007/Annotation: The 80-adult UCSF crossover trial in multiple sclerosis: improved mental health quality of life measures, no serious adverse events, and the authors' statement that dropout and data errors reduced power.
  22. 22.Peer-reviewedSharafaddinzadeh N, Moghtaderi A, Kashipazha D, Majdinasab N, Shalbafan B. The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial. Multiple Sclerosis. 2010;16(8):964-969. https://pubmed.ncbi.nlm.nih.gov/20534644/Annotation: The 96-patient two-center crossover trial in relapsing-remitting and secondary progressive multiple sclerosis: no meaningful between-group difference on MSQoL-54 and the authors' efficacy caveat.
  23. 23.RegulatoryFDA, Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (content current as of 14 May 2026). Accessed 8 November 2026. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
  24. 24.Regulatory21 CFR 216.23, Bulk drug substances that can be used to compound drug products in accordance with section 503A (eCFR, current as of 5 November 2026). Accessed 8 November 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-C/section-216.23
  25. 25.RegulatoryFDA, Human Drug Compounding Laws (content current as of 17 December 2024). Accessed 8 November 2026. https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies
  26. 26.RegulatoryFDA, Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A, Guidance for Industry (January 2018, docket FDA-2016-D-1309). Accessed 8 November 2026. https://www.fda.gov/files/drugs/published/Compounded-Drug-Products-That-Are-Essentially-Copies-of-a-Commercially-Available-Drug-Product-Under-Section-503A-of-the-Federal-Food--Drug--and-Cosmetic-Act-Guidance-for-Industry.pdf

Cite this page

ExaVeyra Sciences Editorial Team. Low Dose Naltrexone: Trials, Reviews and Labels. ExaVeyra Sciences; 9 November 2026. Available from: https://exaveyra.com/science/compounds/low-dose-naltrexone-published-trials. Accessed [date accessed].

Recursos exclusivos para miembros de ExaVeyra

Para prácticas verificadas y aprobadasReservado para profesionales clínicos

Bóveda de investigación

Literatura revisada por pares seleccionada para cada compuesto del catálogo, con un resumen imprimible de dos minutos, la evidencia de un vistazo y los artículos por los que empezar.

  • 266 artículos revisados por pares, cada uno con su enlace DOI o PubMed
  • 8 áreas de investigación
  • 128 revisiones sistemáticas, metaanálisis y ensayos aleatorizados
  • 18 compuestos con un resumen de dos minutos

El registro toma unos dos minutos. El acceso se habilita tras la verificación del NPI y una revisión de nuestro equipo. No se piden datos de pago.

Cada resumen empieza por los diseños de estudio más sólidos y luego los más recientes.

Preguntas frecuentes

What is low dose naltrexone?
Naltrexone is an opioid antagonist approved since 1984 in tablet form for alcohol dependence and for blockade of exogenously administered opioids, and later as an extended-release injection. Low dose naltrexone refers to off-label use of the same molecule at a small fraction of the approved tablet strength, prepared by compounding pharmacies, on the hypothesis that low doses act on microglial toll-like receptor 4 signaling and produce a transient opioid receptor blockade.
What did the largest trial report?
The Danish FINAL trial, published by Bruun and colleagues in 2024, randomized 99 women with fibromyalgia to a daily low dose of naltrexone or placebo for 12 weeks in a quadruple-masked parallel-group design. It did not show superiority over placebo on its primary outcome of pain intensity, and adverse event rates were similar between the groups.
Which trials reported positive results?
The Stanford crossover trials in women with fibromyalgia (10 participants in 2009 and 31 in 2013), the Penn State trial in 40 adults with active Crohn's disease and the Cree crossover trial in 80 adults with multiple sclerosis each reported improvement on their stated outcomes against placebo, and the 14-child Penn State pilot reported a fall in disease activity from pretreatment values. The 2013 Stanford authors called for parallel-group trials, and the Cree authors reported that dropout and data errors reduced the trial's statistical power.
Do the meta-analyses agree?
They do not. The 2024 Vatvani analysis of four randomized trials reported lower pain scores than placebo, while the 2025 Ologunowa analysis of eight trials and the overall estimate in the 2025 Hegde analysis reported no significant difference against control. The 2023 Partridge systematic review graded the randomized evidence as low strength with a high risk of bias.
What safety findings do the labels and trials report?
The approved tablet label reports cases of hepatitis and clinically significant liver dysfunction in association with naltrexone exposure and contraindicates the drug in patients receiving opioid analgesics, patients dependent on opioids and patients in acute opioid withdrawal. The low dose trials report vivid dreams, insomnia and nausea as the recurring adverse events and no serious adverse events attributed to the drug; the Hegde meta-analysis reported a higher adverse event incidence than placebo.
Can a 503A pharmacy compound naltrexone?
Section 503A permits compounding with a bulk drug substance that complies with an applicable USP or NF monograph or is a component of an FDA-approved drug, manufactured by an FDA-registered establishment and accompanied by a certificate of analysis. Naltrexone hydrochloride is the active ingredient of approved products, so it does not depend on the 503A bulks list in 21 CFR 216.23. FDA's 2018 guidance asks the prescriber to document a significant difference for the patient where a compounded strength substitutes for the approved tablet.
How does compounded low dose naltrexone reach a practice through ExaVeyra?
Through ExaVeyra's licensed 503A pharmacy partner on a patient-specific prescription, with a certificate of analysis for each lot available on request. The prescribing practitioner decides whether to prescribe, for which patient, at what strength and with what monitoring.

Esta página se ofrece únicamente con fines informativos. No constituye consejo médico, no está destinada a diagnosticar, tratar, curar ni prevenir ninguna enfermedad, y no sustituye el criterio de un profesional con licencia. Consulte a un profesional de la salud antes de actuar sobre cualquier cosa que aquí se afirme. ExaVeyra Sciences es un proveedor y no participa en ningún diagnóstico, decisión de tratamiento ni plan de atención. Estas referencias informan lo que los ensayos, las revisiones, las etiquetas de los productos y las comunicaciones de la FDA establecen sobre los compuestos que prepara una farmacia 503A asociada, con fines de formación profesional, y no hacen ninguna afirmación sobre la idoneidad de ningún producto para ningún paciente. Cuando esta página trata un producto aprobado por la FDA, rige el etiquetado aprobado y nada de lo aquí expuesto lo modifica. Las preparaciones compuestas son una clase de producto distinta: no son productos farmacéuticos terminados aprobados por la FDA, se preparan bajo la sección 503A de la Ley Federal de Alimentos, Medicamentos y Cosméticos contra una prescripción específica para un paciente, y son productos de prescripción suministrados únicamente a profesionales con licencia. Los ingredientes cosméticos que se tratan aquí se describen dentro del marco regulatorio cosmético y no son medicamentos. La decisión de prescribir corresponde al profesional con licencia. Leer el aviso completo

Solo de referencia. No constituye asesoramiento legal ni médico.

El contenido de estas guías se ofrece únicamente con fines informativos generales. No constituye asesoramiento legal, médico ni regulatorio, y no debe interpretarse como una confirmación de que determinado producto o determinada práctica cumple con la normativa aplicable. Los requisitos regulatorios varían según el estado y dependen de las circunstancias de cada práctica. Cada profesional debe consultar a su propio asesor legal y a las juntas estatales de licenciamiento aplicables antes de actuar sobre cualquier cosa que aquí se afirme.

Leer el aviso completo